Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT4306F, an ADCC-Enhanced CD20 Monoclonal Antibody

americanpharmaceuticalreviewDecember 10, 2018

Tag: Bio-Thera , BAT4306F , ADCC , CD20 Monoclonal

PharmaSources Customer Service